Intravenous Immunoglobulin (IVIg)

Global Market Trajectory & Analytics

MCP-7776

EXECUTIVE ENGAGEMENTS

* Login for a full stack data experience

DATE

APR 2021

TABLES

168

222

EDITION

17

PRICE

USD 5450

*Engagement stats are ongoing and dynamic

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Intravenous Immunoglobulin (IVIg) estimated at US$10.3 Billion in the year 2020, is projected to reach a revised size of US$15.7 Billion by 2027, growing at a CAGR of 6.2% over the analysis period 2020-2027. IgA, one of the segments analyzed in the report, is projected to record a 6.8% CAGR and reach US$5.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the IgD segment is readjusted to a revised 6% CAGR for the next 7-year period.

The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.9% and 4.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5% CAGR.

In the global IgE segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$2.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.8 Billion by the year 2027.

SELECT PLAYERS

Bharat Serums and Vaccines Limited; Biotest AG; China Biologic Products, Inc.; CSL Limited; Grifols, S.A.; Hualan Biological Engineering Inc.; Kedrion S.p.A.; LFB Group; Octapharma AG; Shanghai RAAS Blood Products Co., Ltd.; Shire plc; Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

SEGMENTS

» Type (IgA, IgD, IgE, IgG, IgM) » Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications) » End-Use (Hospitals, Clinics, Homecare Settings) » Segment (Intravenous Immunoglobulin (IVIg))

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Immunoglobulins to See Steady Growth

Recent Market Activity

Intravenous Immunoglobulin - A Proliferating Biologic

Application Areas - A Brief Review

Market Outlook

Growth Drivers and Market Challenges

Competitive Scenario

Grifols Continues to Consolidate Market Position

CSL Sees Robust Growth in Immunoglobulin Franchise

Shire Continues to Invest Big in Immunoglobulins

Bivigam Changes Hands Consequent to Unexpected Turn of Events

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

Bharat Serums and Vaccines Limited (India)

Biotest AG (Germany)

China Biologic Products, Inc. (China)

Guizhou Taibang Biological Products Co., Ltd (China)

CSL Limited (Australia)

Grifols, S.A. (Spain)

Hualan Biological Engineering Inc. (China)

Kedrion S.p.A. (Italy)

LFB Group (France)

Octapharma AG (Switzerland)

Shanghai RAAS Blood Products Co., Ltd. (China)

Shire plc (Ireland)

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

3. MARKET TRENDS & DRIVERS

Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins

Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market

IVIg - The Mainstay of PI Therapy

Subcutaneous IG Formulations Gain Therapeutic Foothold

Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead

Unsuccessful Clinical Trials for Alzheimer's - A major Setback for IVIg Market

Synthetic Replacements to IVIg Therapy

IVIg Therapy - Home-based vs. Outpatient Settings

Per Capita Consumption Rate Varies Across Countries

Favorable Reimbursement and High Usage make US the Largest Consumer

Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID

Aging Global Population: Major Opportunity Indicator

Improving Healthcare Expenditure to Foster Growth

IV. COMPETITION

Total Companies Profiled: 24

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.